Bayer’s Rally Faces a Litmus Test as Judge Chhabria Hears Bid to Dismiss 4,000 Roundup Claims
Published on 07/09/2026 at 13:23 | Redaktion boerse-global.de
Investors who have ridden Bayer’s 42% monthly surge are now watching a San Francisco courtroom as closely as the ticker. Federal Judge Vincent Chhabria is weighing whether to toss out nearly 4,000 bundled glyphosate lawsuits, a decision that could either validate the stock’s explosive rally or expose it to a sharp reversal.
The hearing, originally set for Tuesday and delayed by two days, represents the first major test of Bayer’s legal strategy since the US Supreme Court handed the company a landmark victory in late June. The high court ruled that a federal pesticides law preempts state-level claims over missing cancer warnings on product labels, as long as those labels comply with federal requirements. Bayer is now leaning on that precedent to argue that the vast majority of Roundup cases should be thrown out entirely.
Plaintiff attorneys, led by Robin Greenwald, are pushing back. They contend that the Supreme Court decision only covers labeling defects, not broader allegations such as design flaws or negligence. Judge Chhabria has made clear he is not satisfied with either side’s initial explanations, calling them “unsatisfactory” and demanding more precise legal reasoning before he rules on the dismissal motion.
The stakes extend well beyond the four thousand cases bundled in San Francisco. A separate class-action settlement covering roughly 60,000 claims — valued at $7.25 billion — is scheduled for final approval on August 19 before the Missouri Circuit Court. Bayer supports that deal, which would resolve a huge swath of its remaining Roundup exposure. Before then, the company reports second-quarter earnings on August 4, shifting the market’s focus back to operational performance.
Should investors sell immediately? Or is it worth buying Bayer?
Meanwhile, the stock’s technical picture is flashing caution signals. Bayer shares ended Wednesday at €50.36, just a few percent below the 52-week high of €53.86 set on July 3. The relative strength index stands at 72.4, pushing into overbought territory, and the stock has already given back 5.05% over the past week as some investors lock in profits. The 50-day moving average of €39.62 is now 27% below the current price, underscoring how stretched the rally has become.
Analysts, however, are increasingly confident that the legal overhang is lifting. Goldman Sachs raised its price target to €62.50 from €55, reiterating a buy recommendation as analyst James Quigley reduced the discount on Bayer’s pharma business and lowered his cost-of-capital estimate. Deutsche Bank went a step further, upgrading the stock from hold to buy and lifting its target from €45 to €60. Berenberg was more cautious, keeping its hold rating but still bumping up the target from €40.50 to €55. JPMorgan held its target at €50. The broader analyst consensus, compiled from 18 firms, yields an average price target of €51.92 and an “outperform” rating — now roughly in line with the current share price.
The improving legal outlook is also reigniting speculation about structural change. Market chatter has revived around a potential IPO of Bayer’s crop science division, a move that would have been far harder to execute while the glyphosate liability remained unresolved. The company has already taken preparatory steps, bundling its US glyphosate business under a new entity called Ruveon, which many analysts interpret as a prelude to a deeper restructuring.
Bayer at a turning point? This analysis reveals what investors need to know now.
For now, all eyes are on Judge Chhabria. A dismissal of the 4,000 bundled suits would clear a major hurdle and could push the stock toward the higher end of analyst expectations. A mixed ruling, however, would leave the litigation cloud hanging — and the overbought rally vulnerable to a sharp reality check.
Ad
Bayer Stock: New Analysis - 9 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
